Stockscreener 앱 받기
0.9413
0.92%
-0.0087
시간 외 거래:
.99
0.0487
+5.17%
전일 마감가:
$0.95
열려 있는:
$0.95
하루 거래량:
113.16K
Relative Volume:
0.21
시가총액:
$34.50M
수익:
-
순이익/손실:
$-9.16M
주가수익비율:
-1.6514
EPS:
-0.57
순현금흐름:
$-8.75M
1주 성능:
+2.61%
1개월 성능:
-8.61%
6개월 성능:
-32.76%
1년 성능:
-31.79%
1일 변동 폭
$0.9261
$0.9699
1주일 범위
$0.81
$0.9699
52주 변동 폭
$0.7006
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
명칭
Renovorx Inc
전화
408-800-2649
주소
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
RNXT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.9413 | 34.82M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Renovorx Inc 주식(RNXT)의 최신 뉴스
Is RenovoRx Inc. stock near bottom after declineJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - Newser
What makes RenovoRx Inc. stock attractive to growth funds2025 Momentum Check & Weekly Chart Analysis and Guides - Newser
RenovoRx (RNXT) Stock Analysis Report | Financials & Insights - Benzinga
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th - Investing News Network
RenovoRx CEO to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) CEO to detail RenovoCath updates at iAccess Alpha - Stock Titan
RenovoRx files $50M mixed securities shelf - MSN
Big Money Moves: Is RenovoRx Inc. stock attractive for growth ETFsMarket Trend Review & Safe Entry Zone Tips - BỘ NỘI VỤ
RenovoRx CMO Makes Bold Stock Purchase - TipRanks
[Form 4] RenovoRx, Inc. Insider Trading Activity - Stock Titan
RenovoRx CMO Ramtin Agah Acquires 22,000 Shares - TradingView
Cipla Limited (CIPLA) Gets Regulatory ApprovalFinancial Sector Performance & Stay One Step Ahead of Risk Events - earlytimes.in
Is RenovoRx Inc. stock positioned for long term growthRisk Management & Reliable Volume Spike Trade Alerts - newser.com
Is RenovoRx Inc. stock a top pick in earnings seasonWeekly Profit Report & Community Driven Trade Alerts - newser.com
RenovoRx Expands Reach with RenovoCath Approval - MSN
Is RenovoRx Inc. stock dividend yield sustainablePortfolio Growth Summary & Risk Managed Investment Signals - newser.com
Published on: 2025-11-19 17:29:20 - newser.com
Tick level data insight on RenovoRx Inc. volatility2025 Retail Activity & Safe Investment Capital Preservation Plans - newser.com
How to integrate RenovoRx Inc. into portfolio analysis toolsQuarterly Trade Summary & Weekly High Return Stock Opportunities - newser.com
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th - Investing News Network
RenovoRx CEO Shaun Bagai to Present at Alliance Global Partners Virtual Showcase on Oncology Innovations - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) to Share RenovoCath, $900K YTD Revenue at AGP Showcase - Stock Titan
What drives RenovoRx Inc stock pricePrice Gap Trading Strategies & Go Beyond the Headlines With Analyst Picks - earlytimes.in
Does RenovoRx Inc. fit your quant trading modelJuly 2025 Breakouts & Verified Chart Pattern Signals - newser.com
RenovoRx : Corporate Overview - MarketScreener
Strategic Expansion and Promising Clinical Results Justify Buy Rating for RenovoRx - TipRanks
Can RenovoRx Inc. stock deliver consistent earnings growthJuly 2025 Snapshot & AI Forecasted Entry/Exit Points - newser.com
RenovoRx launches public stock offering - MSN
Is RenovoRx Inc. stock supported by innovation pipelineBull Run & Free Safe Entry Trade Signal Reports - newser.com
Can machine learning forecast RenovoRx Inc. recoveryJuly 2025 Opening Moves & Intraday High Probability Alerts - newser.com
RenovoRx Earnings Call: Positive Momentum and Strategic Growth - MSN
RenovoRx’s Innovative Cancer Treatment and Promising Phase 3 Study Drive Buy Rating - TipRanks
RenovoRx price target lowered to $3 from $3.50 at Alliance Global - MSN
What analyst consensus says on RenovoRx Inc. stockWeekly Investment Recap & Smart Swing Trading Alerts - newser.com
RenovoRx Enters Capital on Demand Sales Agreement - TipRanks
Renovorx Inc (RNXT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.44%
0.91%
자본화:
|
볼륨(24시간):